drug_type
RELEVANT_DRUG
intervention_type
Biological
drug_description
Investigational intravenous bispecific antibody immunotherapy (immune-cell engager) that binds Claudin-6 on tumor cells and an immune effector cell receptor to trigger immune-mediated killing of CLDN6-positive cancers.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Antibodies, Bispecific
drug_category
BISPECIFIC T ENGAGER
drug_class
Engager
drug_delivery_route
Intravenous
drug_mechanism_of_action
ASP1893 is an investigational bispecific antibody that binds Claudin‑6 on tumor cells and a receptor on T cells (e.g., CD3), bringing T cells into close proximity to CLDN6‑positive tumor cells to trigger T‑cell activation and cytotoxic killing.
drug_name
ASP1893
nct_id_drug_ref
NCT06681870